Sandoz moves to block Amgen’s attorneys from prosecuting patents in IP spat

Intellectual Property 2025-05-06 11:41 pm By Andy Sidler | Melbourne

Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.